Objective: Little is known about the incidence of secondary neoplasms among survivors of retinoblastoma in Japan. The objective of our study was to analyze the cumulative incidence rate of secondary neoplasms following retinoblastoma and to investigate the risk factors of developing secondary neoplasms. Methods: We conducted a retrospective cohort study of 754 retinoblastoma patients who visited the National Cancer Center Hospital in Tokyo between 1964 and 2007. The cumulative incidence rate curves were drawn using the competing risk method and compared with the Gray's test. Using competing risk regression analysis, multivariate analysis estimated the subdistribution hazard ratio of factors related to the development of secondary neoplasms. Results: The median length of follow-up was 108 months (0 -594 months). Twenty-one (2.8%) patients developed 23 secondary neoplasms in total. The cumulative incidence rates of secondary neoplasms after retinoblastoma treatment were 2.4% at 10 years after diagnosis, 4.3% at 20 years, 6.4% at 30 years and 19.1% at 40 years. Ten patients (1.3%) died and 723 (95.9%) were alive without developing secondary neoplasms. The subdistribution hazard ratios of hereditary retinoblastoma and external beam irradiation were 4.85 (95% confidence interval ¼ 0.74-31.85) and 4.76 (95% confidence interval ¼ 0.69 -33.09), respectively. Conclusions: We demonstrated the cumulative incidence rate of secondary neoplasms following retinoblastoma in Japan. The subdistribution hazards ratios of hereditary retinoblastoma and external beam irradiation were high but not significant because of statistical power. The long-term follow-up of retinoblastoma survivors is warranted to understand secondary neoplasm risk.
INTRODUCTION
Retinoblastoma (RBL) is the most common intraocular malignancy in children, accounting for approximately 3% of all malignancies in children younger than 15 years of age in the USA (1) . The national registry of RBL in Japan has reported about 70 -90 new cases of RBL per year (2) . About 25% of RBL is hereditary and bilateral, 15% is hereditary and unilateral, and the remaining (60%) is non-hereditary and unilateral (3, 4) . Patients with the hereditary form are at risk of developing secondary neoplasms (SNs) (5, 6) , especially osteosarcomas and soft tissue sarcomas (7) .
Over the last 30 years, the 5-year survival of the RBL cases has been improving. For example, the 5-year survival rate was 96.5% in the USA (1995 -2004) (8) . Therefore, the recent challenge in treating RBL is to improve the quality of life of the patients by preserving the affected eyes and preventing serious side effects from the treatment of the malignancy. SN is one of the most critical issues to confront because it is the major cause of early deaths among RBL survivors (7) .
Systemic chemotherapy (chemoreduction) with focal therapies (9) has become an alternative to external beam irradiation (EBI), a treatment that enhances the risk of developing SNs in hereditary RBL cases (5, 6, 10) . However, little is known about the long-term effect of chemotherapeutic agents on SN development after RBL treatment.
The epidemiology of SNs after RBL treatment has not been thoroughly explored in Japan. Although there are research reports on affected Japanese patients with SNs after RBL treatment, most of them are case reports. No cumulative incidence rate (CIR) of SNs has been reported since 1992 (2) . The purpose of our study is to present the CIR of SNs with longer follow-up time compared with the previous report (2) and to examine relative risks of various factors on SN development.
PATIENTS AND METHODS
We conducted a retrospective cohort study of RBL patients at the National Cancer Center Hospital (NCCH) in Tokyo. We reviewed the medical records of 754 RBL patients who initially visited NCCH between September 1964 and April 2007. The patients were followed until 31 May 2007. The endpoint of the study was defined as the development of an SN. SN was defined as a primary neoplasm, except RBL, which developed after initial RBL treatment. Therefore, RBL relapse and trilateral RBL ( primary neoplasm of the pineal and parasellar sites) were excluded from the category of SN.
The following factors ( patient characteristics) were extracted from the records: (i) basic characteristics at the time of diagnosis (age, sex, laterality of RBL, family history of RBL, the Reese -Ellsworth classification (R -E classification) for the affected eye, metastasis) and (ii) treatments (focal treatments, focal chemotherapy, systemic chemotherapy, EBI, brachytherapy). The R -E classification has been widely used as a guideline for predicting prognosis for eye preservation (11) . Focal treatments consist of photocoagulation, cryotherapy and hyperthermia. Focal chemotherapy refers to the infusion of chemotherapeutic agents either via the ophthalmic artery or directly into the vitreous.
CIR of SNs was calculated using the competing risk method and then it was compared with the Gray's test (12) . The subdistribution hazard ratio of the factors related to SN development was calculated with multivariate analysis using the competing risk regression model (13) . In these analyses, the event of interest was defined as SN development and a competing risk event as death prior to the SN development. The R statistical software (version 2.10.0) was employed to conduct the estimation. A P value of ,0.05 (two-sided) was considered statistically significant when choosing the variables in the final multivariate model. A 95% confidence interval (CI) was calculated for the subdistribution hazard ratio. SPSS 16.0J for Windows (SPSS Japan Inc., Tokyo, Japan) was used for descriptive analysis.
RESULTS
Among the 754 RBL patients whose medical records were reviewed, 21 (2.8%) individuals developed SNs. Ten patients (1.3%) died prior to developing SNs, and 723 patients (95.9%) survived without developing SNs. Table 1 describes the characteristics of the RBL patients. Table 2 shows the regimens of systemic chemotherapy. According to the previous studies (2,12), we defined the hereditary RBL as 'bilateral RBL and/or having family history of RBL' (Table 3) . Median lengths of follow-up were determined as 102 months (the first and third quartiles, 62 -186; range 14 -438) for the patients who developed SNs; 46 (13 -66, 5 -133) for the patients who died prior to developing SNs and 110 (52 -200, 0 -594) for the patients who survived without developing SN.
The 21 affected patients developed 23 SNs in total. Table 4 displays pathological diagnoses of the SNs. Note that one patient developed two Meibomian carcinomas (one for each eyelid), and one patient developed double neoplasms (rhabdomyosarcoma and osteosarcoma). Of all identified SNs, 15 out of 23 (65.2%) were osseous or soft tissue sarcomas (7 were osteosarcomas, 7 were rhabdomyosarcomas and 1 was a myxofibrosarcoma). Others were diagnosed as two Meibomian carcinomas, one acoustic neuroma, one meningioma, one acute myelogenous leukemia and one neuroendocrine tumor. Pathologic diagnoses were not obtained for the remaining two neoplasms because no surgeries were performed on these tumors. Figure 1 shows the CIR of SNs in the presence of a competing risk for the whole series of RBL. The CIRs of SNs every 10 years after RBL treatment were 2.4% at 10 years after diagnosis, 4.3% at 20 years, 6.4% at 30 years and 19.1% at 40 years.
The following six factors were independently associated with SN development in the univariate analysis using the Gray's test (12) : age at diagnosis (0 -11 months: P ¼ 0.035); heredity (hereditary RBL: P , 0.001); focal therapy (yes: P ¼ 0.003); focal chemotherapy (yes: P ¼ 0.005); systemic chemotherapy (yes: P ¼ 0.028) and EBI (yes: P ¼ 0.004). Table 5 demonstrates the CIRs of SNs by heredity.
The relative risks (subdistribution hazards ratio) of SN development were estimated with the six factors above by fitting a proportional subdistribution hazards regression model (13) . Table 6 
DISCUSSION
In our study, the competing risk regression analysis demonstrated that the risks of developing SNs on the two factors, hereditary RBL and EBI, increases more than four times,
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Secondary neoplasms following retinoblastoma although the P values were not statistically significant. Focal chemotherapy and systemic chemotherapy had moderate but not significant associations with SN development (SHR 2.24 and 1.92, respectively). Previous studies documented the strong association between hereditary RBL and SN development (5,6). Abramson reviewed 711 hereditary RBL patients and observed that the CIRs of SNs of their cohort were 20% at 10 years from diagnosis, 50% at 20 years and 90% at 30 years for the irradiated patients, and 10% at 10 years, 30% at 20 years and 68% at 32 years for the non-irradiated patients (5) . These values are much higher compared with those found for our cohort. Roatry examined 215 patients with bilateral RBL where the CIRs of SNs of the cohort were 4.44 % at 10 years, 18.3% at 20 years and 26.1 % at 30 years (6).
Loss of heterozygosity (LOH) on 13q14 of the chromosome has been detected among patients with hereditary RBL (14) . The locus contains the RB1 RBL gene, a tumor suppressor gene originally isolated by Friend et al. (15) . LOH is caused by either deletion of the chromosomal locus (16) or mutation of the RB1 gene (17) , and is detected not only in RBL but also in other malignancies such as osteosarcoma (18) , breast cancer (19) and small cell lung cancer (20) . Hereditary RBL patients are at an increased risk of developing osteosarcomas (7, 21) .
EBI is another risk factor for developing SNs, especially among hereditary RBL patients (5,6,10,22 -25) . The previous study in Japan did not show a significant difference in the CIRs of SNs by irradiation history (2), perhaps because of the small sampling size and the short follow-up period. 
Jpn J Clin Oncol 2011;41(3) 375
The results of our study are consistent with the above studies regarding the risk of hereditary RBL and EBI on SN development. These two factors were statistically significant in the univariate analysis, though not significant in the multivariate analysis probably due to the small number of events. Marees et al. (25) CIRs of SNs among hereditary or irradiated patients using the Kaplan -Meier method, though they did not report P values or carry out a log-rank test. Because we took a competing risk method (death prior to developing SN), the result might be more conservative than the one estimated by Cox's regression analysis.
Our study showed that systemic chemotherapy had moderate association with SN development. So far, we could not conclude whether systemic chemotherapy is a risk factor for SN or not for two reasons. First, there was a discrepancy in the follow-up time between the different treatments in the The total number of cases does not match that in Table 1 , because some patients underwent multiple courses/regiments of chemotherapy.
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Secondary neoplasms following retinoblastoma cohort; i.e. the length of follow-up was shorter for the patients who received systemic chemotherapy (median 48 months, range 0 -401) compared with those who received EBI (median 131 months, range 5 -500), and this might have underestimated the effect of systemic chemotherapy.
Second, we did not stratify the cohort according to the chemotherapeutic regimens because they were rich in variety and the stratification of the regimen would much further decrease the statistical power. There were moderate associations between regional treatments (focal therapy and focal chemotherapy) and SN development. However, the authors did not interpret these treatments as risk factors for SN development. The reason is that the effects of the treatments are confined to the regional RBL; thus, theoretically speaking, they would not be expected to induce extra-ocular neoplasms. The association might have been due to a confounding effect because those treatments were selectively applied to hereditary RBL cases.
Regarding the risk of chemotherapy, several studies have indicated that treatment with alkylating agents and topoisomerase II inhibitors (epipodophyllotoxins and anthracyclines) increased the probability of secondary acute myeloid leukemia (sAML) (26 -29) . Gombos et al. reported in their retrospective study that there was a high incidence of sAML in RBL patients after chemotherapy with topoisomerase II inhibitors, where 12 out of 15 sAML cases of their cohort had received topoisomerase II inhibitors (30) . Chemoreduction without topoisomerase II inhibitors had There are two limitations of this study. First, we could not include R -E classification in the analysis because the classification is the feature per eye compared with other independent variables, which are the features per individual. The mixture of variously staged patients might have pulled the result toward null or could have inflated the true findings. Second, the shorter follow-up period of the patients after systemic chemotherapy could have underestimated the potential treatment effect. Further follow-up of these patients should improve the accuracy of the study.
Our study has three advantages. First, this is the first report of the CIR of SNs among RBL patients in Japan since 1992. Second, no study has ever used an analytical method considering 'competing risks' on the long-term follow-up of pediatric cancer patients in Japan. Competing risks are events for which the occurrence of some other event does not allow the event to occur (32) . They may preclude the onset of the event of interest or may modify the probability of the onset of the event of interest (33) . (In our study, a death prior to SN development is defined as a competing risk, which prevents the event of interest, namely SN development.) Analytical methods that take competing risks into consideration (12) have an advantage over the Kaplan -Meier estimation procedure because the latter assumes that any subject who does not experience the event of interest as censored could thus miss information from the competing risks. Third, although our cohort is limited to a single institution, the size of the cohort is relatively large compared with the entire population of Japanese RBL patients; an estimated 80 children per year develop RBL in Japan (2) . In addition, none of our patients were missed from the follow-up.
Our study suggests that the RBL patients, especially hereditary ones and those who received EBI, should be closely monitored for the risk of developing SNs. Since the CIR of SNs increases along with the time course of the disease, attention to adult survivors is particularly important.
Although the risk of systemic chemotherapy on SN development is not completely denied, we consider it rational to apply such a treatment to carefully selected patients whose benefits of preserving a functioning eye outweigh the risk of developing SN.
CONCLUSION
Our study was the first since 1992 to reveal the CIR of SNs after RBL treatment in Japan. The study also suggested the risk of hereditary RBL and EBI on SN development. The long-term follow-up of RBL patients should be pursued in order to provide further information on SNs.
